Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA
tacalyx has raised €18M across 2 funding rounds from 7 investors, most recently a Seed round in Apr 2026. Based in Berlin, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
